Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
MRK last changed hands at $148.64 (up 0.38%). At $366.72B, Merck & Co is ranked #35 by size among the 300 stocks on BeStock.
Over the past 52 weeks it has traded between $75.80 and $156.00, so it sits 4.7% below the top of that range. Holders are ahead 90.9% over twelve months, and up 23.3% across the last three months.
On the chart it holds above both the 50-day ($139.27) and 200-day ($120.30) moving averages; RSI is 59, and the last 30 sessions moved at roughly 42% annualized volatility.
Revenue for the quarter ended Jun 2026 was $16.61B, up 5.1% from a year earlier, and a net loss of $1.34B.
Valuation works out to 118.9 times trailing earnings, 61% above its five-year average of 73.8. The median for its industry group is 20.4.
18 analysts follow the stock and the average call is "buy". The mean target, $163.16, sits 9.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Merck sells the cancer immunotherapy Keytruda, vaccines like Gardasil, and animal health products.
What tends to move it. Keytruda's patent expiry around 2028 and the success of its replacement pipeline are the key debates.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +0.7% | Bullish |
| Price vs 50-day average | +6.7% | Bullish |
| Price vs 200-day average | +23.6% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 58.9 | Bullish |
| MACD (12,26,9) | 2.26 | Bearish |
| Bollinger band position | 59% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 89th percentile, 5-year average 73.8x
#2806 of 2977 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 97th percentile, 5-year average 6.0x
#4756 of 5303 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 96th percentile, 5-year average 4.3x
#3904 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$164.52M (7 inflow days, 13 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 7.4% a year.
$148.64 is the latest print for MRK, a move of +0.38% against yesterday's close of $148.08. Today's low and high so far: $148.01 and $151.46.
Equity value comes to $366.72B at the current price. By that measure it is number 35 of the 300 names in our coverage.
Buyers pay 118.9 times the last twelve months of profit (EPS $7.28). Averaged over five years the multiple has been 73.8, and today's level ranks in the 89th percentile of its own history.
The year's floor is $75.80 and the ceiling $156.00. Shares are 4.7% away from that ceiling.
It does. Payouts over the past twelve months work out to a 2.26% yield; the latest ex-dividend date was September 15, 2026.
Of 18 analysts, 83% say buy, 17% hold and 0% sell. Price targets average $163.16, with the most cautious at $125.00 and the most optimistic at $180.00.
Merck sells the cancer immunotherapy Keytruda, vaccines like Gardasil, and animal health products.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.